Aligos Therapeutics, Inc.
NCM: ALGSLive Quote
📈 ZcoreAI Score
Our AI model analyzes Aligos Therapeutics, Inc.'s price action across multiple timeframes using regression channels and statistical scoring.
Get ALGS Z-Score →About Aligos Therapeutics, Inc.
Healthcare
Biotechnology
Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in liver and viral diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis and obesity. The company also develops pevifoscorvir sodium, a capsid assembly modulator, which is in Phase 2 B clinical trial; and ALG-097558, a small molecule ritonavir-free pan-coronavirus protease inhibitor which has completed a Phase 1 clinical trial for the treatment of coronavirus. The company has entered into license and research collaboration agreement with Emory University; and Katholieke Universiteit Leuven. Aligos Therapeutics, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.
📊 Fundamental Analysis
Aligos Therapeutics, Inc. demonstrates a profit margin of 0.0%, which is below the sector average, suggesting competitive pressure.
The company recently reported -73.1% revenue growth, which is negative, indicating a recent decline in revenue.
Return on Equity (ROE) is -196.9%, which indicates that capital utilization is currently under pressure.
At a current price of $8.00, ALGS currently sits at the 40th percentile of its 52-week range (Range: $4.13 - $13.69).
🏥 Financial Health
🔴
Profit Margin
Weak
✅
Debt/Equity
Excellent
🔴
Revenue Growth
Weak
🔴
Return on Equity
Weak
🔴
Beta (Risk)
High Volatility
Key Financials
Market Cap
$49.47M
Trailing P/E
--
Forward P/E
-1.50
Beta (5Y)
2.62
52W High
$13.69
52W Low
$4.13
Avg Volume
51K
Day High
Day Low